Prostate Cancer

... (To be presented in a poster discussion on Monday, April 3, 1:00 - 5:00 p.m.

EDT) (Abstract ID: 2894) - Local secretion of anti-CTLA-4 antibody from a GM-CSF-secreting tumor cell vaccine enhances vaccine efficacy (To be presented in mini-symposia on Sunday, April 2, 3:25 - 3:40 p.m.

EDT) (Abstract ID: 1520) - EGFR inhibitors decrease the potency of GM-CSF-secreting tumor cell vaccines by inhibiting T-cell activation.

(To be presented in a poster discussion on Sunday, April 2, 1:00 - 5:00 p.m.

EDT) (Abstract ID: 1398) - An armed oncolytic vector (OV1203) expressing E.

coli purine nucleoside phosphorylase (PNP) combined with Fludara(TM) shows increased efficacy.

(To be presented in mini-symposia on Tuesday, April 4, 11:40 - 11:55 a.m.

EDT) (Abstract ID: 4022) Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer.

The company is currently pursuing two clinical stage product platforms - GVAX® cancer immunotherapies and oncolytic virus therapies.

Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for ne...

... CFD Therapeutics Formed to Advance Novel Monoclonal Antibodies for Cancer CFD Therapeutics Formed to Advance Novel Monoclonal Antibodies for Cancer SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire/ - diaDexus, Inc.

and San Francisco-based Biotechnology Value Fund L.P.

(BVF) today jointly announced the formation of a new spin-out company, CFD Therapeutics, Inc.

(CFD), to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus.

CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus.

BVF has made an initial investment in CFD, through which it has assumed majority ownership in the company.

diaDexus provided an exclusive license to CFD for its entire portfolio of therapeutic targets and associated monoclonal antibodies.

CFD's programs will leverage over eight years and more than $100 million of novel target discovery and antibody development efforts carried out at diaDexus.

Through its founding partnership with Incyte Genomics in 1997 and its own discovery program, diaDexus identified genes that are highly over-expressed in cancerous relative to normal tissue.

Starting from thousands of candidate genes, diaDexus identified approximately 20 promising candidates to move forward into pre-clinical development as therapeutic antibody targets.

"We have selected ...

... South Bend Tribune March 30, 2006 Contact Us Print Story March 30.

2006 6:59AM Wrestling with God Tribune staff writer comes to grips with life through His people By HOWARD DUKESTribune Staff Writer Part 4 of a seriesI always knew I'd end up in somebody's oncology unit.

See, my father had cancer.

Died from it in 2000.

But still, I was surprised by my diagnosis last year.Guess I was thinking genetics is destiny and I'd go out like Pops - enlarged prostate in my late 50s, cancer about 13 years later, die from it about 10 years after that.

I'd be almost 80.

But that's not how it went down.

I was 41.It wouldn't be the first time my expectations about the way things should go clashed with how they went.

The first time was when my older sister died.Regina had always been sick, but I thought she'd seen the worst of it.

She was 15 and I was 13, and I felt I was becoming more than the annoying little brother.

I looked forward to our teenage years.

We'd go to football and basketball games in high school, and she'd hook me up with her friends.And then one day, it was all gone.That day was Dec.

14, 1977.

A gray, slushy Wednesday.

The paper said there were 10 shopping days until Christmas.

Regina had been home sick for a few days.My mother picked me up from school, dropped off some car-poolers and headed home.

We found Regina lying ...